Pleiotropic effects of mitiglinide in type 2 diabetes mellitus.
This study investigated the effects of mitiglinide in 16 patients with type 2 diabetes mellitus treated with 30 mg/day mitiglinide, divided into three doses given just before each meal, for approximately 12 months. A 450 kcal meal tolerance test was performed at baseline and after 3, 6 and 12 months, and levels of plasma glucose and immunoreactive insulin were measured. Various parameters of glucose metabolism and lipid metabolism, urinary albumin and markers of atherosclerosis, coagulation and fibrinolysis were also determined. Mitiglinide showed a rapid stimulatory effect on insulin secretion and reduced the levels of plasma glucose. The free fatty acid level significantly decreased at 60 min after the meal tolerance test. Mitiglinide also significantly lowered glycosylated haemoglobin and raised 1,5-anhydroglucitol after 6 months, and significantly decreased urinary albumin after 12 months. These data indicate that mitiglinide may have beneficial effects not only on glycaemic control but also on lipid metabolism and urinary albumin excretion, and may have a role in the prevention of the vascular complications of diabetes.
Konya
H
H
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. h-dyer@mvi.biglobe.ne.jp
Miuchi
M
M
Konishi
K
K
Nagai
E
E
Ueyama
T
T
Kusunoki
Y
Y
Kimura
Y
Y
Nakamura
Y
Y
Ishikawa
T
T
Inokuchi
C
C
Katsuno
T
T
Hamaguchi
T
T
Miyagawa
J
J
Namba
M
M
D000419:Albuminuria / Q000150:complications; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003847:Deoxyglucose / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005215:Fasting / Q000097:blood; D005227:Fatty Acids / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D054833:Isoindoles / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period / Q000187:drug effects; D012044:Regression Analysis
D015415:Biomarkers; D001786:Blood Glucose; D003847:Deoxyglucose; D005227:Fatty Acids; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054833:Isoindoles; D008055:Lipids; C006584:1,5-anhydroglucitol; C087255:mitiglinide